Inactive Instrument

Sunesis Pharmaceuticals, Inc. Stock Nasdaq

US8673286014

Chart Sunesis Pharmaceuticals, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc. Announces Executive Changes	21-02-24	CI
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-24	CI
Sunesis Pharmaceuticals, Inc.(NasdaqCM:SNSS) dropped from NASDAQ Composite Index	21-02-24	CI
Viracta Therapeutics, Inc. completed the acquisition of Sunesis Pharmaceuticals, Inc. for approximately $100 million in a reverse merger transaction.	21-02-23	CI
SUNESIS PHARMACEUTICALS : Oppenheimer Upgrades Sunesis Pharmaceuticals to Outperform from Perform, Sets $12 Price Target	21-02-23	MT
Sunesis Pharmaceuticals, Inc. Announces Board Changes	20-12-22	CI
Sunesis Pharmaceuticals, Inc. Announces Executive Changes	20-12-22	CI
Sunesis Pharmaceuticals, Inc. Announces Executive Changes	20-12-22	CI
Sunesis Pharmaceuticals : to Combine with Viracta Therapeutics in All-Stock Deal	20-11-30	MT
Transcript : Sunesis Pharmaceuticals, Inc., Viracta Therapeutics, Inc. - M&A Call	20-11-30
Viracta Therapeutics, Inc. executed the Offer Letter to acquire Sunesis Pharmaceuticals, Inc. in a reverse merger transaction	20-11-29	CI
Sunesis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Sunesis Pharmaceuticals : Q3 Beats Street Estimates	20-11-16	MT
Transcript : Sunesis Pharmaceuticals, Inc., Q3 2020 Earnings Call, Nov 16, 2020	20-11-16
Sunesis Pharmaceuticals : Earnings Flash (SNSS) SUNESIS PHARMACEUTICALS Reports Q3 EPS $-0.29	20-11-16	MT

More news

Analyst Recommendations on Sunesis Pharmaceuticals, Inc.

SUNESIS PHARMACEUTICALS : Oppenheimer Upgrades Sunesis Pharmaceuticals to Outperform from Perform, Sets $12 Price Target

21-02-23

More recommendations

Press releases Sunesis Pharmaceuticals, Inc.

SUNESIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	21-02-24	AQ
SUNESIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	21-02-24	AQ
SUNESIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	21-02-23	AQ
SUNESIS PHARMACEUTICALS INC : Other Events (form 8-K)	21-02-12	AQ
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS	20-12-29	BU

More press releases

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company's lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton's Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).

Sector

More about the company